InterCure Ltd. INCR
3.61 USD -0.02 (-0.56%)
Regular-session close
3.61 0.00 +0.01%
After hours · Nov 17, 4:00 PM ET
3.56 Day range 3.64
3.12 52-week range 7.55
- YTD
- -20.67%
- 1 year
- -47.23%
- Market cap
- 46.83M
- Revenue (ttm)
- 272.67M
- Profit margin
- -24.07%
- EPS (ttm)
- -0.95
- Shares out
- 45.77M
- Forward P/E
- -1.21
- YTD return
- -20.67%
- 1-year return
- -47.23%
- Volume
- 4.34K
- Avg volume
- 24.93K
- Open
- 3.56
- Previous close
- 3.63
- Day's range
- 3.56 – 3.64
- 52-week range
- 3.12 – 7.55
- Beta
- 0.03
- 50-day average
- 1.52
No chart data for this range yet.
Key statistics
- 200-day average
- 2.14
- Enterprise value
- 203.36M
- Price / sales
- 0.30
- Price / book
- 0.19
- Revenue growth
- -38.60%
- Total cash
- 20.30M
- Total debt
- 150.81M
- Return on equity
- -13.61%
- Short % of float
- 0.15%
Fundamental scorecard
9 of 25 checks passed on INCR’s reported financials
9of 25 checks passed
- Value 3 of 5
- Growth 3 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Dec 31, 2025.
Financials — quick view
INCR Revenue — quarterly 102.44M
INCR Net income — quarterly 4.88M
INCR EPS — quarterly 0.525
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 31, 2023 | Jun 1, 2023 | 0.00 | 0.03 | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
| Mar 31, 2023 | Dec 1, 2022 | 0.00 | 0.05 | — | — |
| Nov 15, 2022 | Sep 1, 2022 | 0.00 | 0.05 | — | — |
| Aug 15, 2022 | Jun 1, 2022 | 0.00 | 0.10 | — | — |
| May 16, 2022 | Mar 1, 2022 | 0.00 | 0.11 | — | — |
About InterCure Ltd.
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- intercure.co
News
Comparing Tilray Brands (NASDAQ:TLRY) and InterCure (NASDAQ:INCR)
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
InterCure (NASDAQ:INCR) & Silo Pharma (NASDAQ:SILO) Financial Review
InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
Your note
Sign in to keep a note on INCR — it syncs with the Stock Master app.
